Format

Send to

Choose Destination
Cannabis Cannabinoid Res. 2017 Oct 1;2(1):259-264. doi: 10.1089/can.2017.0033. eCollection 2017.

Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention.

Author information

1
Department of Neurology, Mayo Clinic, Rochester, Minnesota.

Abstract

Introduction: The endocannabinoid system (ECS) regulates functions throughout human physiology, including neuropsychiatric, cardiovascular, autonomic, metabolic, and inflammatory states. The complex cellular interactions regulated by the ECS suggest a potential for vascular disease and stroke prevention by augmenting central nervous and immune cell endocannabinoid signaling. Discussion: The endocannabinoid N-arachidonoylethanolamine (anandamide) plays a central role in augmenting these processes in cerebrovascular and neurometabolic disease. Furthermore, cannabidiol (CBD), a nonpsychoactive constituent of Cannabis, is an immediate therapeutic candidate both for potentiating endocannabinoid signaling and for acting at multiple pharmacological targets. Conclusion: This speculative synthesis explores the current state of knowledge of the ECS and suggests CBD as a therapeutic candidate for stroke prevention by exerting favorable augmentation of the homeostatic effects of the ECS and, in turn, improving the metabolic syndrome, while simultaneously stalling the development of atherosclerosis.

KEYWORDS:

anandamide; cannabidiol; obesity; stroke prevention; vascular disease

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center